Taysha Gene Therapies Announces Participation in Upcoming March Investor Healthcare Conferences

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats for the Oppenheimer 31st Annual Healthcare Conference and Stifels 3rd Annual CNS Day.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, March 11, 2021
Information
Tags: 
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Branches of biology, Life sciences, Biology, Biotechnology, Gene delivery, Applied genetics, Molecular biology, Emerging technologies, Therapy, Gene therapy, Monogenic
Geotags: 
United States, Texas, UT
⚠ generated by AI ↴
Organisation: 
TAYSHA GENE THERAPIES
Summary
Key Points: 
  • Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats for the Oppenheimer 31st Annual Healthcare Conference and Stifels 3rd Annual CNS Day.
  • Audio webcasts for these conferences will be available in the Events & Media section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations .
  • Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease.
  • We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications.


Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats for the Oppenheimer 31st Annual Healthcare Conference and Stifel’s 3rd Annual CNS Day.

Conferences Details:

Event: Oppenheimer 31st Annual Healthcare Conference (Virtual)

Date: Tuesday, March 16, 2021

Time: 1:50 pm ET

Format: Fireside chat

Participants: RA Session II, President, Founder and CEO

Event: Stifel’s 3rd Annual CNS Day (Virtual)

Date: Wednesday, March 31, 2021

Time: 10:30 am ET

Format: Fireside chat

Participants: RA Session II, President, Founder and CEO

Audio webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Copyright: 
Copyright Business Wire 2021